• Explore /
  • Poster
  • / Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC).

Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

Michael Morris

Michael J. Morris

Memorial Sloan-Kettering Cancer Center, New York, NY

Michael J. Morris , Neeta Pandit-Taskar , Jorge A. Carrasquillo , Joseph A. O' Donoghue , John Humm , Serge K. Lyashchenko , Eric C. Haupt , Neil Harrison Bander , Scott T. Tagawa , Jason P. Holland , Peter M. Smith-Jones , Jason Stuart Lewis , Stephen Barnett Solomon , Howard I. Scher , Steven M. Larson

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session A: Prostate Cancer

Track

Prostate Cancer

Sub Track

Prostate Cancer

Clinical Trial Registration Number

NCT01543659

Citation

J Clin Oncol 31, 2013 (suppl 6; abstr 31)

DOI

10.1200/jco.2013.31.6_suppl.31

Abstract #

31

Poster Bd #

C4

Abstract Disclosures

Similar Posters

First Author: Michael J. Morris

First Author: Mark T. Fleming

First Author: Jarett L. Feldman

First Author: Jarett L. Feldman